Name
Address/P.O. Box Postal Code/City Country Contact Person Telephone Fax Email Website Social Media Number of Employees Founded (year) Type of Laboratory
Areas of Activity
External Collaborations
Request for Further Collaborations
›
ERBC (European Research Biology Center)
›
Headquarters: Chemin de Montifault 18800 Baugy France Frank Visser (Chief Commercial Officer) +39-06-91095263 +39-06-9122233 fvisser@erbc-group.com www.erbc-group.com
›
I
› › › › › › ›
› › ›
›
›
›
270 1972 Translational research, safety pharmacology, toxicology, from routine analysis to highly complex and customized studies | New Chemical Entity | Oligonucleotide | Protein | Peptide | Monoclonal antibody | Vaccine | Cellular therapy | Gene therapy | Excipient | Chemicals | Biocide | Plant protection products | Food & Feed Collaborations with pharmaceutical, biotech, chemical companies and CROs, from preclinical proof of concept to market Our business development team is happy to discuss your project and find tailor-made solutions for you challenges. Please do not hesitate to contact us at info@erbc-group.com
ERBC – the non-clinical engine Born on 1st November 2019, when CERB (France) acquired the toxicology activities from RTC (Italy). By merging the complementary portfolios of pharmacology and toxicology, a new full service provider was created and renamed to ERBC. ERBC is now a European leader in non-clinical studies to de-risk innovation and improve R&D productivity, offering all services from non-clinical proof-of-concept to market of any type of drug-candidate or chemical compound: › Comprehensive suite of experimental capabilities, preclinical models, regulatory pre-IND package and consultancy services › Multidisciplinary team of experts (>200 FTE), including leaders in safety cardiology, DART, electrophysiology and pathophysiology › >16,000 sqm facilities, with more than half dedicated to laboratories and animal housing › Deeply engaged in animal ethics and welfare Every year, study reports from our two Centres are successfully used in support of market authorization and new product approval submissions around the world, including the European (EMA, ECHA), US (FDA and EPA) and Japanese (MHLW and MAFF) regulatory authorities. Investment in outstanding scientific and technical manpower, high-tech equipment and facilities are crucial cornerstones of our growth. The quality and reliability of our performance is reflected by the many ongoing and long-lasting collaborations we maintain with leading international pharmaceutical and chemical companies. We innovate with 5 to 10 new models or methodological procedures every year.
Translational research With over 200 validated methods and models, a facilitated access to patient samples and a world class academic and industrial network, ERBC is uniquely positioned to establish the preclinical proof-of-concept of any therapies.
